Biotech Investors & VC Firms in Singapore

85 firms in this list, with a median first check of $826K. 19 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
HI Hillhouse Capital Leads rounds	88🔒	Changyang	CN	Seed–Series C	$2.9M – $220M	+ Add to CRM
MI Mizuho Capital KH1 person	88🔒	Tokyo	JP	Pre-Seed–Late Stage	$1.5M – $340M	+ Add to CRM
IN INP Capital JGNBJCSX6 people	88🔒	Vancouver	CA	Seed–Late Stage	—	+ Add to CRM
BA Baidu Ventures Follows rounds	88🔒	Beijing	CN	Pre-Seed–Growth	$1.4M – $145M	+ Add to CRM
JA JAFCO Group	88🔒	Tokyo	JP	Pre-Seed–Late Stage	$1.9M – $198M	+ Add to CRM
VE VentureTECH	88🔒	Selangor	MY	Series A–Late Stage	$1.6M – $10M	+ Add to CRM
EL Elmirate Capital Leads rounds	88🔒	Dubai	AE	Seed–Late Stage	$1M – $250M	+ Add to CRM
UN Unveil Pharma JC1 person	88🔒	Boston	US	Pre-Seed–Series A	—	+ Add to CRM
JA Japan Asia Investment SM1 person	88🔒	Tokyo	JP	Pre-Seed–Late Stage	$1M – $10M	+ Add to CRM
10 10x Genomics ASJSPCDJ4 people	88🔒	Pleasanton	US	—	—	+ Add to CRM
EP ePlanet Capital AAAJYL3 people	88🔒	San Jose	US	Seed–Late Stage	—	+ Add to CRM
FR Frees Fund	88🔒	Beijing	CN	Pre-Seed–Series B	$425K – $35M	+ Add to CRM
HS HSBC Innovation Ventures YQ1 person	88🔒	London	GB	Seed–Growth	—	+ Add to CRM

Hillhouse Capital

ChangyangSeed–Series C$2.9M – $220M

Mizuho Capital

TokyoPre-Seed–Late Stage$1.5M – $340M

KH1 person

INP Capital

VancouverSeed–Late Stage

JGNBJCSX6 people

Baidu Ventures

BeijingPre-Seed–Growth$1.4M – $145M

JAFCO Group

TokyoPre-Seed–Late Stage$1.9M – $198M

VentureTECH

SelangorSeries A–Late Stage$1.6M – $10M

Elmirate Capital

DubaiSeed–Late Stage$1M – $250M

Unveil Pharma

BostonPre-Seed–Series A

JC1 person

Japan Asia Investment

TokyoPre-Seed–Late Stage$1M – $10M

SM1 person

10x Genomics

Pleasanton

ASJSPCDJ4 people

ePlanet Capital

San JoseSeed–Late Stage

AAAJYL3 people

Frees Fund

BeijingPre-Seed–Series B$425K – $35M

HSBC Innovation Ventures

LondonSeed–Growth

YQ1 person

Data sourced from public filings and firms' own websites — see our methodology.